In 2021, reports from the Semaglutide Treatment Effect for People with Obesity (STEP) trials provided evidence of the effect of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), on reducing body weight in patients without diabetes [12,13,14]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.